So just take a look guys and gals: Oncology: IMBRUVICA ® developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA ® licensed from BTG International Ltd., VELCADE ® developed in collaboration with Millennium: The Takeda Oncology Company, DARZALEX ® licensed from Genmab A/S, PROCRIT ®/EPREX ® licensed from Amgen Inc., and Imetelstat licensed from Geron Corporation This isn't an exercise in perfection. Look at that list folks! WE HAVE BEEN INCLUDED ON THAT LIST OF CRAZY, SUCCESSFUL, DRUGS!! Maybe I'm reading more into it than it's worth, but LOOK AT THAT LIST!!!! Imetelstat mentioned in the same breath as Imbruvica?
We have entered into Phase 3 for IMERGE (They are recruiting participants): Here's what the current presentation from Geron says about the Part 1, Part 2 (Phase 3): - Part 1 (Phase 2) to evaluate safety and efficacy of imetelstat to advance to Part 2 based on positive assessment of benefit-risk profile in significant unmet medical need population - Part 2 (Phase 3) to compare imetelstat to placebo using an established regulatory endpoint
Now here's what the IMERGE Trials data posted on Geron's web site says as of June 29: This study is currently recruiting participants. (It shows 46 locations are recruiting - I believe this is different than the 30 patients they recruited for Part 1) See Contacts and Locations Verified June 2017 by Janssen Research & Development, LLC Sponsor: Janssen Research & Development, LLC Information provided by (Responsible Party): Janssen Research & Development, LLC ClinicalTrials.gov Identifier: NCT02598661 First received: October 27, 2015 Last updated: June 29, 2017 Last verified: June 2017
NEW patent ? United States Patent 9,708,360 Pongracz , et al. July 18, 2017 Phosphorodiamidate backbone linkage for oligonucleotides
Abstract This invention relates to antisense oligonucleotides comprising at least one N3'.fwdarw.P5' phosphorodiamidate linkage (NPN) in the backbone, and kits and pharmaceutical compositions thereof, useful for modulating gene expression involved in the pathogenesis of a disease. Also included are compounds useful as building blocks of said antisense oligonucleotides and methods of preparing said antisense oligonucleotides and building block compounds including NPN linkages.
Inventors: Pongracz; Krisztina (Oakland, CA), Ramaseshan; Mahesh (Sunnyvale, CA) Applicant: Name City State Country Type
Geron Corporation Menlo Park CA US Assignee: Geron Corporation (Menlo Park, CA) Family ID: 1000002711482 Appl. No.: 14/498,872 Filed: September 26, 2014
I need some news, these student loans arent to get paid off just on my salary! Come on Chip, throw me something!!
Think of it this way. Buy 34 million shares of GERN stock tomorrow and see where GERN's price runs to. It will be somewhere north of $50 a share.
Very rough sales numbers of the JNJ listed Oncology drugs, from a Google search: Imbruvica - $2 billion Zytiga - $9 billion Velcade - $7 billion Darzalex - $9 billion Eprex and Procrit - $2 billion Imetelstat - TBD
From JNJ-webcast July 18, Billions in sales projections from pipeline opportunities- 2017 Strategic Partnerships, Collaborations & Licensing Arrangements: During the course of this morning’s presentations, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. Following is an acknowledgement of those relationships. Oncology IMBRUVICA® developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA® licensed from BTG International Ltd., VELCADE® developed in collaboration with Millennium: The Takeda Oncology Company, DARZALEX® licensed from GenmabA/S, PROCRIT®/EPREX® licensed from Amgen Inc., and Imetelstat licensed from Geron Corporation. The best news: the Menlow Park A-team overall survival test is going great.
oh donkey dee donkey doo clutters the board with half wit spew lacks the brains to make the ^A^ fud team so he pulls his pud and blows out steam.
JnJ/Janssen is currently running 205 clinical trials in 1122 locations. JnJ/Janssen ranks Imetelstat in their top 10. Looking Good
GERN is a train coming down the tracks and the shorts with their 34 million shorted shares are laying on the tracks. Johnson and Johnson are pouring the coal to this locomotive as with Johnson and Johnsons presentation this week calling GERN 1 of JNJ top 6 money making drugs.
Per clinical trials.gov identifier NCT02598661...they are recruiting for phase 3. Verified June 2017 by jannssen per the website. Isn't this what we were waiting on? Pardon the ignorance if wrong.
Seeing Imetelstat in the J&J report today as one of the top 6 oncology drugs, I came off my hold position and started buying Gern again.
Johnson and Johnson again yesterday called GERN's drug one of Johnson and Johnson top future money makers. Worth over $1 billion a year and yet the shorts with their 34 million shorted shares keep saying NOT TRUE, NOT TRUE. I hear panic in the short sellers texting here.
Should Senator John McCain start infusing on Imetelstat? Discuss.
I sure hope Mr William W. Basher has finally told a truth..Although i seriously doubt it..Can he really go away until the phase 3 decision? Per his very own post...If you have your eyes closed, you can't post
WilliamW3 hours ago Steven, ****I'M CLOSING MY EYES AND HOLDING UNTIL THE PHASE 3 UP/DOWN DECISION****..
Johnson and Johnson just keeps bragging about GERN this week and JNJ is pushing GERN's technology forward to the max all while the shorts sit on 34 million shorted GERN shares. This is going to be really good for the people that own GERN stock. Short squeeze is coming.
GERN is under $3 only because the shorts have sold 34 million shares of invisible GERN stock that has to bought back yet at a much higher price. Seeking Alpha said that when the shorts cover GERN will soar to over $19 a share.
1 GERON share will be =1 J&J share soon.
pumpers are so ineffective! can't even get this turd to 2.90.